Risk Factors Update Summary
- The portfolio companies in the healthcare & pharmaceuticals industry increased from 10% to 11%.
- The transition from LIBOR to SOFR could negatively impact market value and liquidity.
- The global capital markets were unstable between 2008 and 2009, with disruptions in liquidity.
- The Board's failure to comply with SBA regulations could have an adverse impact.
- The number of members on the investment committee decreased from five to four.
- The investment advisory agreement was renegotiated in 2023, impacting services and costs.
- Investments in the high tech industry increased from 10.52% to 10.77%.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1551901&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.